Publications for Lars-Åke Levin
Co-author map based on ISI articles 2007-

Publications mentioned in social media 11 times*

Keywords

utilization trial treatment stroke risk quality qaly patients landsting kronor invasive heart health guidelines failure dr dabigatran cost-effectiveness coronary cardiovascular

Journal Articles

Kristina Burström, Sun Sun, Ulf-G Gerdtham, Martin Henriksson, Magnus Johannesson, Lars-Åke Levin and Niklas Zethraeus
  Swedish experience-based value sets for EQ-5D health states
  Quality of Life Research, 2014, 23(2), 431-442.
 Web of Science® Times Cited: 1

Lars-Åke Levin, Lars Wallentin, Lars Bernfort, David Andersson, Robert F. Storey, Gina Bergstrom, Carl-Johan Lamm, Magnus Janzon and Padma Kaul
  Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial
  Value in Health, 2013, 16(4), 574-580.
 Web of Science® Times Cited: 2

Thomas Davidson, Magnus Husberg, Magnus Janzon, Jonas Oldgren and Lars-Åke Levin
  Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
 
Altmetric usage: 4

  European Heart Journal, 2013, 34(3), 177-183.
 Web of Science® Times Cited: 11

Leif Friberg, Johan Engdahl, Viveka Frykman, Emma Svennberg, Lars-Åke Levin and Marten Rosenqvist
  Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)
 
Altmetric usage: 2

  Europace, 2013, 15(1), 135-140.
 Web of Science® Times Cited: 5

Emelie Heintz, Marieke Krol and Lars-Åke Levin
  The impact of patients' subjective life expectancy on time trade-off valuations
  Medical decision making, 2013, 33(2), 261-270.
 Web of Science® Times Cited: 2

Ola Granström, Lars-Åke Levin and Martin Henriksson
  Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension.
 
Altmetric usage: 1

  ClinicoEconomics and outcomes research : CEOR, 2012, 4, 313-322.
   Fulltext  PDF  

Talitha I Verhoef, William K Redekop, Rianne M F van Schie, Samira Bayat, Ann K Daly, Mary Geitona, Elisabeth Haschke-Becher, Dyfrig A Hughes, Farhad Kamali, Lars-Åke Levin, Vangelis G Manolopoulos, Munir Pirmohamed, Uwe Siebert, Julia C Stingl, Mia Wadelius, Anthonius de Boer and Anke-Hilse Maitland-van der Zee
  Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs
 
Altmetric usage: 2

  Pharmacogenomics (London), 2012, 13(12), 1405-1417.
 Web of Science® Times Cited: 3

Emelie Heintz, Ann-Britt Wiréhn, Beatrice Bourghardt Peebo, Ulf Rosenqvist and Lars-Åke Levin
  QALY weights for diabetic retinopathy: a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.
 
Altmetric usage: 1

  Value in Health, 2012, 15(3), 475-484.
 Web of Science® Times Cited: 3

Billie Pettersson, Mikael Hoffmann, Per Wändell and Lars‐Åke Levin
  Utilization and Costs of Glucose‐ lowering Therapies following Health Technology Assessment for the new reimbursement scheme in Sweden
  Health Policy, 2012, 108(2-3), 207-215.

U Alstrom, Lars-Åke Levin, E Stahle, Rolf Svedjeholm and O Friberg
  Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery
  British Journal of Anaesthesia, 2012, 108(2), 216-222.
 Web of Science® Times Cited: 3

Billie Pettersson, Mikael Hoffmann, Per Wandell and Lars-Åke Levin
  Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden
 
Altmetric usage: 1

  Health Policy, 2012, 104(1), 84-91.
 Web of Science® Times Cited: 5

Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation
  Journal of Atrial Fibrillation, 2011, 2(4), 00-00.

Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies
  Scandinavian Cardiovascular Journal, 2011, 45(2), 72-76.
   Fulltext  PDF  

Lars Grip, Bertil Lindahl, Lars-Åke Levin, Christina Karvinge, Kristina Eklund and Lars Wallentin
  From European to National guidelines on heart disease
  SCANDINAVIAN CARDIOVASCULAR JOURNAL, 2011, 45(1), 3-13.
 Web of Science® Times Cited: 1

M Henriksson, D Russell, J Bodegard, S Kjeldsen, P Hasvold, J Stalhammar and Lars-Åke Levin
  Health-care costs of losartan and candesartan in the primary treatment of hypertension
  JOURNAL OF HUMAN HYPERTENSION, 2011, 25(2), 130-136.
 Web of Science® Times Cited: 2

Emelie Heintz, Ann-Britt Wiréhn, Beatrice Peebo Bourghardt, U Rosenqvist and Lars-Åke Levin
  Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden
  Diabetologia, 2010, 53(10), 2147-2154.
 Web of Science® Times Cited: 16

Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson and Magnus Janzon
  Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
  AMERICAN HEART JOURNAL, 2010, 160(2), 322-328.
 Web of Science® Times Cited: 6

Thomas Davidson and Lars-Ake Levin
  Is the societal approach wide enough to include relatives?: incorporating relatives' costs and effects in a cost-effectiveness analysis.
  Applied Health Economics and Health Policy, 2010, 8(1), 25-35.

L. Grip, K. Eklund, L. Weilandt, Lars-Åke Levin and B. Lindahl
  Ingen evidens för nyttan av ny policy vid asymtomatisk preexcitation
  Läkartidningen, 2009, 106(50), .

Nathalie Eckard, Thomas Davidson, Håkan Walfridsson and Lars-Åke Levin
  Cost-Effectiveness of Catheter Ablation Treatment for Patients with Symptomatic Atrial Fibrillation
  Journal of Atrial Fibrillation, 2009, 1(8), 461-470.

Emelie Heintz, Thor-Henrik Brodtkorb, Nina Nelson and Lars-Åke Levin
  The long-term cost-effectiveness of fetal monitoring during labour: a comparison of cardiotocography complemented with ST analysis versus cardiotocography alone
  British Journal of Obstetrics and Gynecology, 2008, 115, 1676-1687.
 Web of Science® Times Cited: 13

Thomas Davidson and Lars-Åke Levin
  Do individuals consider expected income when valuing health states?
  International Journal of Technology Assessment in Health Care, 2008, 24(4), 488-494.
 Web of Science® Times Cited: 7

Thomas Davidson, Barbro Krevers and Lars-Åke Levin
  In pursuit of QALY weights for relatives: Empirical estimates in relatives caring for older people
  European Journal of Health Economics, 2008, 9(3), 285-292.
 Web of Science® Times Cited: 5

Urban Alehagen, Mikael Rahmqvist, Thomas Paulsson and Lars-Åke Levin
  Quality-adjusted life year weights among elderly patients with heart failure
  European journal of heart failure, 2008, 10(10), 1033-1039.
 Web of Science® Times Cited: 8

Douglas Lundin, Per Carlsson, Lars-Åke Levin and Ulf Persson
  Analys av kostnadseffektivitet i samhällsekonomiskt perspektiv
  Läkartidningen, 2006, 103(47), 3716-3718.

Örjan Friberg, Lars-Göran Dahlin, Lars-Åke Levin, Anders Magnusson, Hans Granfeldt, Jan Källman and Rolf Svedjeholm
  Cost effectiveness of local collagen-gentamicin as prophylaxis for sternal wound infections in different risk groups
  Scandinavian Cardiovascular Journal, 2006, 40(2), 117-125.
 Web of Science® Times Cited: 16

Urban Alehagen, G Lindstedt, Lars-Åke Levin and Ulf Dahlström
  Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population
  International Journal of Cardiology, 2005, 100(1), 125-133.
 Web of Science® Times Cited: 27

Urban Alehagen, G. Lindstedt, Lars-Åke Levin and Ulf Dahlström
  The risk of cardiovascular death in elderly patients with possible heart failure: results from a 6-year follow-up of a Swedish primary care population
  International Journal of Cardiology, 2005, 100(1), 17-27.
 Web of Science® Times Cited: 10

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial
  American Heart Journal, 2004, 148(1), 114-121.
 Web of Science® Times Cited: 19

Anna Strömberg, J. Mårtensson, Bengt Fridlund, Lars-Åke Levin, Jan-Erik Karlsson and Ulf Dahlström
  Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: Results from a prospective, randomised trial
  European Heart Journal, 2003, 24(11), 1014-1023.
 Web of Science® Times Cited: 163

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
  Heart, 2003, 89(3), 287-292.
 Web of Science® Times Cited: 4

Agneta Andersson, John Carstensen, Lars-Åke Levin and Bengt Göran Emtinger
  Costs of informal care for patients in advanced home care: a population based study
  International Journal of Technology assessment in Health Care, 2003, 19(4), 656-663.
 Web of Science® Times Cited: 12

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Comment concerning 'Cost-effectiveness of an invasive strategy in unstable coronary artery disease' - Reply
  European Heart Journal, 2002, 23(20), .

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost-effectiveness of an invasive strategy in unstable coronary artery disease: results from the FRISC II invasive trial
  European Heart Journal, 2002, 23(1), 31-40.
 Web of Science® Times Cited: 26

Agneta Andersson, Lars-Åke Levin, Birgitta Öberg and Linda Månsson
  Health care and social welfare costs in home-based and hospital-based rehabilitation after stroke
  Scandinavian Journal of Caring Sciences, 2002, 16(4), 386-392.
 Web of Science® Times Cited: 10

Agneta Andersson, Lars-Åke Levin and Bengt Göran Emtinger
  The economic burden of informal care
  International Journal of Technology Assessment in Health Care, 2002, 18(1), 46-54.
 Web of Science® Times Cited: 15

Lars-Åke Levin and D Bergqvist
  Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery
  PharmacoEconomics (Auckland), 2001, 19(5 II), 589-597.
 Web of Science® Times Cited: 10

Agneta Andersson, K. Ström, H. Brodin, M. Alton, G. Boman, P. Jakobsson, A. Lindberg, M. Uddenfeldt, H. Walter and Lars-Åke Levin
  Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis
  European Respiratory Journal, 1998, 12(6), 1284-1289.

Books

Lars-Åke Levin, Karin Sennfält, Magnus Janzon, Martin Henriksson, Agneta Andersson and Lars Bernfort
  En introduktion i hälsoekonomi
  AstraZeneca Sverige AB, 2004.


Anthologies

Johan Calltorp, Per Carlsson, Stefan Holmström, Lars-Åke Levin and Jan Persson
  Att beställa hälso- och sjukvård: teori och praktik utifrån fem exempel
  Beställarnätverket för landstingen i Sverige, 1998.


Chapters in Books

Lars-Åke Levin
  Hälsoekonomiskt underlag
  Strokesjukvård: Vetenskapligt underlag för Nationella riktlinjer 2009, Socialstyrelsen, 2009, 151-170.


Conference Articles

Håkan Walfridsson, J Cosedis Nielsen, A Johannessen, P Raatikainen, J Hartikainen, Ulla Walfridsson, Lars-Åke Levin, Magnus Janzon, M Aronsson and P S Hansen
  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden
  ESC Congress 2013, 31 August - 04 September 2013, Amsterdam, Netherlands, 2013.


M Aronsson, Magnus Janzon, Håkan Walfridsson, Ulla Walfridsson and Lars-Åke Levin
  Cost-effectivesness of catheter ablation as first-line treatment for paroxysmal atrial fibrillation
  On behalf of the MANTRA-RAP study Group, 2013.


M. Henriksson, Elisabet Nikolic, Magnus Janzon, O. Hauch, Lars-Åke Levin and L. Wallentin
  LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY in VALUE IN HEALTH, vol 14, issue 3, pp A40-A40
  VALUE IN HEALTH, 2011.


 Web of Science® Times Cited: 2

H Patel, M Schaufelberger, Tiny Jaarsma and Lars-Åke Levin
  Are there enough hospital beds to care for an aging population with chronic diseases in the furute? - is there another option? (oral presentation)
  Första Nationella Hälsoekonomiska konferensen (SHEA), Göteborg, 2011.


Josefine Persson, Gunilla Forsberg-Wärleby, Ingvar Karlberg, Christian Blomstrand and Lars-Åke Levin
  Anhörigas stöd till yngre strokepatienter i ett långtidsperspektiv (muntlig presentation)
  Första Nationella Hälsoekonomiska konferensen (SHEA), Göteborg, 2011.


Magnus Janzon, Elisabet Nikolic, Martin Henriksson, Lars-Åke Levin, Ole Hauch, DB Mark, P. Cowper, P. Kaul, RA. Harrington, J. Horrow and Lars Wallentin
  Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns
  The American Heart Association 2010 Scientific Sessions, Chicago, IL, USA, November 13-17 2010, 2010.


Emelie Heintz, Bourghardt B. Peebo, Ann-Britt Wiréhn, U. Rosenqvist and Lars-Åke Levin
  QUALITY-ADJUSTED LIFE-YEAR (QALY) WEIGHTS ASSOCIATED WITH DIFFERENT SEVERITY LEVELS OF DIABETIC RETINOPATHY in VALUE IN HEALTH, vol 13, issue 7, pp A297-A297
  VALUE IN HEALTH, 2010.


M. Henriksson, D. Russell, S.E. Kjeldsen, J. Bodegard, P. Hasvold and Lars-Åke Levin
  HEALTH CARE COSTS OF LOSARTAN AND CANDESARTAN IN THE PRIMARY TREATMENT OF HYPERTENSION in JOURNAL OF HYPERTENSION, vol 28, issue , pp E240-E241
  JOURNAL OF HYPERTENSION, 2010.


Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for hearts diseases (Abstract)
  Value in Health, 2010.


Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for heart diseases (Poster)
  ISPOR 13th Annual European Congress. Prag Tjeckien, 2010.


Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  The cost of atrial fibrillation in Sweden (Poster)
  Value in Health, 2010.


Martin Henriksson, Magnus Janzon, M. Aasa, Elisabet Lundborg (Nikolic), L. Svensson, J. Herlitz, L. Grip and Lars-Åke Levin
  Cost-effectiveness of very early treatment strategies for acute ST-elevation myocardial infarction based on the Swedish early decision (SWEDES) reperfusion trial (oral presentation)
  SMDM Europe,2008, 2008.


Nathalie Eckard, Martin Henriksson, Thomas Davidson, Håkan Walfridsson and Lars-Åke Levin
  Cost-effectiveness of catheter ablation versus antiarrhytmic drugs for patients with symptomatic atrial fibrillation (oral presentation)
  SMDM Europe,2008, 2008.


Thomas Davidson and Lars-Åke Levin
  Do individuals consider expected income when valueing health states?
  iHEA, the 6th world congress on health economics,2007, 2007.


Magnus Janzon, Mikael Aasa, Johan Lyth, Leif Svensson, Johan Herlitz, Lars Grip and Lars-Åke Levin
  Cost and effectiveness comparison of very early treatment with primary percutaneous coronary intervention facilitated with abciximab or thrombolytic therapy for acute ST-elevation myocardial infarction
  ACC,2007, 2007.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Invasive treatment in non ST elevation acute coronary syndorme promotes long-term health related quality of life - results from the FRISC II trial
  ACC, New Orleans, LA,2007, 2007.


Thomas Davidson, Barbro Krevers and Lars-Åke Levin
  Identification and Estimation of Relatives' QALY Weights for Use in Health Economic Evaluations
  ECHE, 6th European Conference in Health Economics,2006, 2006.


Thomas Davidson and Lars-Åke Levin
  Using the costs of added life-years in a cost-effectiveness analysis
  HTAi, 2nd Annual HTAi Meeting - Bringing HTA into practice,2005, 2005.


Lars-Åke Levin, M Janzon and Eva Swahn
  Long-term cost-effectiveness of invasive strategy in patient with unstable coronary artery disease results from the FRISC-II trial
  Value in Health, 2003.


Per Carlsson, Erling Karlsson, Christina Kärvinge and Lars-Åke Levin
  National guidelines for heart diseases in Sweden - A model for oper vertical priority-setting
  ISTACH annual conference, Canmore, Canada 22-25 June 2003 (poster presentation),2003, 2003.


A Stromberg, J Martensson, B Fridlund, JE Karlsson, Lars-Åke Levin and Ulf Dahlström
  Follow up at a nurse-led heart failure clinic after hospitalization, effects on morbidity, mortality and self-care behavior. Results from a randomized study
  Circulation, 2002.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina - Individual and public preferences differ in levels but are similar when measuring changes over time
  European Heart Journal, 2002.


A Stromberg, J Martensson, B Fridlund, JE Karlsson, Lars-Åke Levin and Ulf Dahlström
  Effects of follow-up after hospitalisation at a nurse-led heart failure clinic: a randomiced trial
  European Heart Journal, 2002.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina. Individual and public preferences differ in levels but are similar when measuring changes over time
  ISTAHC-konferens, Berlin, juni 2002,2002, 2002.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost-effectiveness of early invasive treatment in unstable coronary artery disease: A one-year follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2001.


 Web of Science® Times Cited: 1

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Quality of life one year after invasive intervention in unstable coronary artery disease: Results from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2001.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cast-comparison of early invasive versus non-invasive treatment in unstable coronary artery disease - A six months follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2000.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable coronary artery disease - A comparison of early invasive versus non-invasive treatment. Six months follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2000.


Ph.D. Theses

Emelie Heintz
  Health economic aspects of diabetic retinopathy
  2012.


  Fulltext PDF

Billie Pettersson
  Lipid‐modifying and glucose-lowering therapies in clinical practice: The impact of guidelines and changing reimbursement schemes
  2012.


  Fulltext PDF

Jenny Alwin
  Assessment of Support Interventions in Dementia: Methodological and Empirical Studies
  2010.


  Fulltext PDF

Thomas Davidson
  How to include relatives and productivity loss in a cost‐effectiveness analysis
  2009.


  Fulltext PDF

Lars Bernfort
  Setting priorities in health care: Studies on equity and efficiency
  2001.


Lars-Åke Levin  Myocardial infarction: Costs and benefits of prevention and treatments
  1991.


Reports

Thomas Davidson, Lars-Åke Levin and Anders Bergström
  En pilotstudie av självtestning vid behandling med oral antikoagulantia: Hälsoekonomiska aspekter
  CMT Rapport, 2013:1, 2013.


  Fulltext PDF

Lars Bernfort and Lars-Åke Levin
  QALY som effektmått inom vården. Möjligheter och begränsningar: Kapitel 1. Bakgrund till QALY som effektmått
  CMT Rapport, , 2012.


Per Carlsson, Mikael Hoffmann, Lars-Åke Levin, Lars Sandman and Johanna Wiss
  Prioritering och finansiering av läkemedel för behandling av patienter med sällsynta sjukdomar
  Prioriteringscentrum, 2012:1, 2012.


Lars-Åke Levin
  Tillstånd med negativa QALY-vikter och mätning av temporära hälsotillstånd: Kapitle 4 i QALY som effektmått inom vården. Möjligheter och begränsningar
  CMT Rapport, 2012:2, 2012.


Lars-Åke Levin, David Andersson, Anders Anell, Emelie Heintz, Mikael Hoffman, Andrea Schmidt and Per Carlsson
  Styrformer för effektiv läkemedelsanvändning
  CMT Rapport, 2010:2, 2011.


  Fulltext PDF

Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  CMT rapport: kostnader och kostnadseffektivitet av ett införande av dabigatran hos patienter med förmaksflimmer
  CMT Rapport, 2011:1, 2011.


  Fulltext PDF

Mikael Rahmqvist, Lars-Åke Levin and Ulf Stenestrand
  Utvärdering av Socialstyrelsens riktlinjer för prioritering i hjärtsjukvård 2001-2006
  Rapport / PrioriteringsCentrum, 3, 2008.


Thomas Davidson and Lars-Åke Levin
  Närståendes konsekvenser: Hur kan de inkluderas i den hälsoekonomiska analysen?
  CMT Rapport, 2008:4, 2008.


  Fulltext PDF

Mikael Rahmqvist, Lars-Åke Levin and Ulf Stenestrand
  Utvärdering av Socialstyrelsens riktlinjer för prioritering i hjärtsjukvård 2001-2004
  2006.


Mari Berglind, Simone Ignatova, Lars-Åke Levin, Olle Larkö and Inger Rosdahl
  Uppskattning av antal patienter med basalcellscancer i Sverige under 2003 samt kostnader för diagnostik och behandling
  SSI-rapport / Statens strålskyddsinstitut - SSI ; Swedish Radiation Protection Institute, 7, 2006.


Thomas Davidson and Lars-Åke Levin
  Kostnaden för förmaksflimmer i Östergötland
  CMT Rapport, 2006:5, 2006.


  Fulltext PDF

Mikael Rahmqvist and Lars-Åke Levin
  Hur påverkas sjukvården i praktiken? Utvärdering av Socialstyrelsens riktlinjer för prioritering av hjärtsjukvård. Utgångsläget 2001-2003
  PrioriteringsCentrum, 5, 2005.


Bengt Jönsson, Göran Arvidsson, Lars-Åke Levin and Clas Rehnberg
  Hälsa, vård och tillväxt
  2004.


* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.